CheckMate914
Por um escritor misterioso
Descrição
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
PDF) Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
Strengthening Our Grip on Immuno-Oncology in Genitourinary Cancers: Understanding Science Through Stories
CheckMate914
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
de
por adulto (o preço varia de acordo com o tamanho do grupo)
-1.jpg)
